Open-Label Study to Determine the Effect of Trans Sodium Crocetinate (TSC) on Intra-Tumoral Oxygen Concentration, Tolerability, and Pharmacokinetics of TSC in Post-Operative Patients With High Grade Glioma (HGG).
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Transcrocetinate sodium (Primary)
- Indications Glioma
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Sponsors Diffusion Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 15 Sep 2009 Actual patient number (1) added as reported by ClinicalTrials.gov.
- 15 Sep 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.